SOPHiA GENETICS Raises $77 Million to Accelerate the Democratization of Data-Driven Medicine

San Francisco (ots/PRNewswire) -

SOPHiA GENETICS, a leading health tech company, announced today
the closing of a $77 million investment round to accelerate the
democratization of Data-Driven Medicine. The round was led by
Generation Investment Management, a pioneer of sustainable investing,
with offices in London and San Francisco. Generation were joined by
Idinvest Partners, a European leader in private equity, alongside
existing investors including Balderton Capital and Alychlo.

(Logo:
https://mma.prnewswire.com/media/803982/SOPHiA_GENETICS_Logo.jpg )

(Photo:
https://mma.prnewswire.com/media/803983/SOPHiA_GENETICS.jpg )

SOPHiA GENETICS was founded in Switzerland and is now co-based in
Lausanne and Boston. The company combines deep expertise in life
sciences and medical disciplines with mathematical capabilities in
data computing. Today, its universal platform, SOPHiA AI, is utilized
by more than 850 hospitals across 77 countries and has already
supported the diagnosis of over 300,000 patients. The platform
enables healthcare professionals to make sense of complex genomic and
radiomic data through advanced analysis in order to better diagnose
and treat patients, both for oncology and hereditary disorders.

With the new funding round, SOPHiA GENETICS has now raised a total
of $140 million. This latest investment will allow the company to
further grow the global community of hospitals using its technology.
In particular, SOPHiA GENETICS will continue adding talent to
reinforce its rapidly expanding presence in the US.

"Generation are delighted to partner with SOPHiA GENETICS. We
believe that leveraging genetic sequencing and advanced digital
analysis will enable a more sustainable healthcare system. SOPHiA
GENETICS is a leader in the preventive and personalized medicine
revolution, enabling the development of targeted therapeutics,
thereby vastly improving health outcomes," said Lilly Wollman,
co-head of Generation's Growth Equity team. "We admire SOPHiA
GENETICS not just for its differentiated analytics capability across
genomic and radiomic data, but also for its exceptional team and
culture."

"Since we founded the company, our goal has been to help make the
global healthcare system more sustainable. By helping clinical
researchers leverage their expertise and work together as a
community, patients all over the world can receive equal access to
better care. Generation Investment Management and SOPHiA GENETICS are
guided by the same belief. With Generation's support, we will enable
the more rapid adoption of Data-Driven Medicine technology in
healthcare for the benefit of patients worldwide," commented Dr.
Jurgi Camblong, CEO and Founder of SOPHiA GENETICS.

About SOPHiA GENETICS

Leader in Data-Driven Medicine, SOPHiA GENETICS is a health tech
company which has developed SOPHiA AI, the advanced technology
helping healthcare professionals make sense of the large amount of
clinical data. SOPHiA GENETICS is democratizing Data-Driven Medicine
by enabling the rapid adoption of genomic and radiomic analysis
worldwide, turning data into actionable clinical insights, and
sharing knowledge through its community. The company's achievements
and innovative approach are recognized by MIT Technology Review's "50
Smartest Companies 2017" and Fast Company's "Most Innovative
Companies 2018." More info: SOPHiAGENETICS.COM
(https://sophiagenetics.com/), follow @SOPHiAGENETICS
(https://twitter.com/SOPHiAGENETICS).

About Generation

Generation Investment Management LLP is dedicated to long-term
investing, integrated sustainability research and client alignment.
It is an independent, private, owner-managed partnership established
in 2004, with offices in London and San Francisco. Generation
Investment Management LLP is authorized and regulated in the United
Kingdom by the Financial Conduct Authority. www.generationim.com

ots Originaltext: Sophia Genetics
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Tarik Dlala
tdlala@sophiagenetics.com
+41-78822-2928

Original-Content von: Sophia Genetics, übermittelt durch news aktuell